7 stories mentioning KALV
Every FINWIRES story that references KALV, newest first.
KalVista Pharmaceuticals (KALV) has an average rating of hold and mean price target of $28.60, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
KalVista Pharmaceuticals (KALV) has an average rating of overweight and mean price target of $31.60, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
KalVista Pharmaceuticals (KALV) has an average rating of overweight and mean price target of $34, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Health care stocks declined late Wednesday afternoon, with the NYSE Health Care Index down 0.6% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.9%.The iShares Biotechnology ETF (IBB) fell 1.5%.In corporate news, Boston Scientific (BSX) shares fell 3.3% after Daiwa Securities downgraded the stock to neutral from outperform, and lowered its price target to $60 per share from $83 earlier.AbbVie (ABBV) raised its full-year outlook on Wednesday as the biopharmaceutical company recorded better-than-expected Q1 results, driven by robust revenue growth from its Skyrizi and Rinvoq immunology drugs. Its shares rose 3.7%.AstraZeneca (AZN) will invest 300 million pounds ($404.9 million) in the UK, focusing on its sites in Cambridge and Macclesfield, in a move aimed at boosting the country's life sciences sector, Bloomberg reported. AstraZeneca shares were down 1.1%.KalVista Pharmaceuticals (KALV) and Chiesi Group said Wednesday they have signed an agreement through which Chiesi will buy KalVista for $27 per share in cash, or about $1.9 billion. KalVista shares surged 38%.
Health care stocks declined Wednesday afternoon, with the NYSE Health Care Index down 0.8% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.9%.The iShares Biotechnology ETF (IBB) fell 2%.In corporate news, AbbVie (ABBV) raised its full-year outlook on Wednesday as the biopharmaceutical company recorded better-than-expected Q1 results, driven by robust revenue growth from its Skyrizi and Rinvoq immunology drugs. Its shares rose 3.4%.AstraZeneca (AZN) will invest 300 million pounds ($404.9 million) in the UK, focusing on its sites in Cambridge and Macclesfield, in a move aimed at boosting the country's life sciences sector, Bloomberg reported. AstraZeneca shares were down 1.2%.KalVista Pharmaceuticals (KALV) and Chiesi Group said Wednesday they have signed an agreement through which Chiesi will buy KalVista for $27 per share in cash, or about $1.9 billion. KalVista shares surged nearly 39%.
KalVista Pharmaceuticals (KALV) and Chiesi Group said Wednesday they have entered into a definitive agreement through which Chiesi will acquire KalVista for $27 per share in cash, or about $1.9 billion. The deal is expected to close in Q3, they said.Shares surged 39% as intraday trading volume rose to over 48.2 million, from a daily average of roughly 984,000.Silicon Motion Technology (SIMO) reported a year-over-year surge in Q1 non-GAAP earnings and sales late Tuesday, beating market expectations.Shares soared 31% as intraday trading volume jumped to over 2.66 million from a daily average of about 623,000.Bloom Energy (BE) reported Q1 adjusted earnings late Tuesday of $0.44 per diluted share, up from $0.03 a year earlier. Analysts polled by FactSet expected $0.12. The company's revenue also handily beat the analysts' forecast.Shares jumped 22% as intraday trading volume surged to over 13.8 million from a daily average of about 10.8 million.Price: $26.71, Change: $+7.47, Percent Change: +38.80%
The Dow Jones Industrial Average and the S&P 500 Index were down, while the Nasdaq Composite was roughly flat in late-morning trading Wednesday amid an ongoing blockade of Iranian ports by the US and ahead of the Federal Reserve's decision on interest rates in the afternoon.The US Senate Banking Committee on Wednesday voted 13-11 to advance Kevin Warsh's nomination as the next Fed chair, according to media reports.In company news, Visa (V) reported fiscal Q2 adjusted earnings late Tuesday of $3.31 per diluted share, up from $2.76 a year earlier and above the FactSet consensus analyst estimate of $3.10. Fiscal Q2 revenue was $11.23 billion, up from $9.59 billion a year ago and above the FactSet consensus of $10.75 billion. Visa said its board authorized a new $20 billion multi-year share buyback program in April. The company also said it has expanded its Agentic Ready program to clients in the Asia Pacific and Latin America regions to prepare the payment sector for AI agent-led commerce. Visa shares were up 8.6% around midday.Robinhood Markets (HOOD) reported Q1 earnings late Tuesday of $0.38 per diluted share, up from $0.37 a year earlier but below the FactSet consensus of $0.39. First-quarter revenue was $1.07 billion, up from $927 million a year earlier but below the FactSet consensus of $1.14 billion. The company said its board updated its share buyback authorization to $1.5 billion in March. Robinhood shares were down 13.3%.KalVista Pharmaceuticals (KALV) and Chiesi Group said Wednesday they have entered into a definitive agreement through which Chiesi will acquire KalVista for $27 per share in cash, or about $1.9 billion. The deal is expected to close in Q3, they said. KalVista shares were up 38.9%.NXP Semiconductors (NXPI) reported Q1 non-GAAP earnings late Tuesday of $3.05 per diluted share, up from $2.64 a year earlier and above the FactSet consensus of $2.98. First-quarter revenue was 43.18 billion, up from $2.84 billion a year ago and above the FactSet consensus of $3.16 billion. For Q2, the company said it expects non-GAAP EPS of $3.29 to $3.72 on revenue of $3.35 billion to $3.55 billion. Analysts polled by FactSet expect $3.21 and $3.28 billion, respectively. NXP shares were up 23.7%.Seagate Technology (STX) reported fiscal Q3 non-GAAP earnings late Tuesday of $4.10 per diluted share, up from $1.90 a year earlier and above the FactSet consensus of $3.51. Fiscal Q3 revenue was $3.11 billion, up from $2.16 billion a year ago and above the FactSet consensus of $2.96 billion. For fiscal Q4, the company said it expects non-GAAP EPS of $5.00, plus or minus $0.20, above the FactSet consensus of $3.99. Fiscal Q4 revenue is expected to be $3.45 billion, plus or minus $100 million, above the FactSet consensus of $3.16 billion. Seagate shares were up 14.2%.Price: $336.58, Change: $+27.28, Percent Change: +8.82%